Filter your results
- 3
- 3
- 3
- 2
- 1
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
|
|
sorted by
|
|
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trialThe Lancet Respiratory Medicine, 2021, 9 (3), pp.295-304. ⟨10.1016/S2213-2600(20)30556-7⟩
Journal articles
hal-03579180v1
|
||
|
Targeted therapy in patients with PIK3CA-related overgrowth syndromeNature, 2018, 558 (7711), pp.540 - 546. ⟨10.1038/s41586-018-0217-9⟩
Journal articles
hal-01877949v1
|
||
|
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe PneumoniaJAMA Internal Medicine, 2021, 181 (1), pp.32-40. ⟨10.1001/jamainternmed.2020.6820⟩
Journal articles
hal-03579175v1
|